ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.9605C>T (p.Pro3202Leu) (rs397507432)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000216276 SCV000275485 uncertain significance Hereditary cancer-predisposing syndrome 2018-04-18 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Insufficient or conflicting evidence,In silico models in agreement (benign)
Color RCV000216276 SCV000911442 benign Hereditary cancer-predisposing syndrome 2016-10-06 criteria provided, single submitter clinical testing
Counsyl RCV000031837 SCV000488573 uncertain significance Breast-ovarian cancer, familial 2 2016-04-28 criteria provided, single submitter clinical testing
GeneDx RCV000436771 SCV000527617 likely benign not specified 2016-05-09 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Integrated Genetics/Laboratory Corporation of America RCV000436771 SCV000916937 uncertain significance not specified 2017-09-18 criteria provided, single submitter clinical testing Variant summary: The BRCA2 c.9605C>T (p.Pro3202Leu) variant involves the alteration of a non-conserved nucleotide. 3/5 in silico tools predict a benign outcome for this variant. This variant was found in 1/246194 control chromosomes at a frequency of 0.0000041, which does not exceed the estimated maximal expected allele frequency of a pathogenic BRCA2 variant (0.0007503). The variant has been shown in functional studies to have no impact on splicing (Houdayer_2012). One reputable database reported two co-occurrences of this variant and a BRCA2 pathogenic variant (BRAC Share). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as likely benign and VUS, without evidence for independent evaluation. Taken together, this variant is classified as VUS.
Invitae RCV000196044 SCV000253063 likely benign Hereditary breast and ovarian cancer syndrome 2017-11-06 criteria provided, single submitter clinical testing
Sharing Clinical Reports Project (SCRP) RCV000031837 SCV000054445 uncertain significance Breast-ovarian cancer, familial 2 2012-05-01 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.